United States Ostomy Drainage Bags Market Outlook to 2025

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Introduction 5

2.1 What Is This Report About? 5

2.2 Ostomy Drainage Bags Market Segmentation 5

2.3 Definitions of Markets Covered in the Report 6

3 Ostomy Drainage Bags Market, United States 8

3.1 Ostomy Drainage Bags Market, United States, Revenue ($m), 2015-2025 8

3.1.1 Colostomy Market, United States, Revenue ($m), by Segment, 2015-2025 10

3.1.2 Ileostomy Market, United States, Revenue ($m), by Segment, 2015-2025 12

3.1.3 Urostomy Market, United States, Revenue ($m), by Segment, 2015-2025 14

3.2 Ostomy Drainage Bags Market, United States, Volume (Units), 2015-2025 16

3.2.1 Colostomy Market, United States, Volume (Units), by Segment, 2015-2025 18

3.2.2 Ileostomy Market, United States, Volume (Units), by Segment, 2015-2025 20

3.2.3 Urostomy Market, United States, Volume (Units), by Segment, 2015-2025 22

3.3 Ostomy Drainage Bags Market, United States, Average Price ($), 2015-2025 24

3.4 Ostomy Drainage Bags Market, United States, Distribution Share by Revenue ($m), 2019 26

3.5 Ostomy Drainage Bags Market, United States, Company Share by Revenue ($m), 2019 27

4 Overview of Key Companies in United States, Ostomy Drainage Bags Market 28

4.1 Hollister Inc 28

4.1.1 Company Overview 28

4.2 Coloplast A/S 28

4.2.1 Company Overview 28

4.3 ConvaTec Group Plc 28

4.3.1 Company Overview 28

4.4 B. Braun Melsungen AG 29

4.4.1 Company Overview 29

5 Ostomy Drainage Bags Market Pipeline Products 30

6 Recent Developments 31

6.1 Corporate Communications 31

6.1.1 Feb 10, 2020: Chi-Med highlights updated phase II Savolitinib / Imfinzi combination data in advanced papillary renal cell carcinoma at 2020 ASCO Genitourinary Cancers Symposium 31

6.1.2 Jan 08, 2020: Midatech Pharma: Positive results from MTD201-102 study support subcutaneous route for long-acting octreotide product 32

6.1.3 Jan 08, 2020: Anavex Life Sciences issued new U.S. patent for ANAVEX2-73 treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis 34

6.1.4 Dec 23, 2019: Mayo Clinic names chief digital officer to lead transformative digital strategy, create Center for Digital Health 35

6.1.5 Dec 03, 2019: Dr. John Halamka named president of Mayo Clinic Platform 35

6.1.6 Sep 13, 2019: FDA clears GE’s AI algorithms to identify pneumothorax 36

6.1.7 Aug 19, 2019: Merit Medical announces appointment of Lynne N. Ward to its Board of Directors 37

6.1.8 Jul 01, 2019: Medline mourns passing of co-founder Jim Mills 38

6.2 Financial Announcements 39

6.2.1 Feb 24, 2020: Merit Medical reports earnings for fourth quarter and year ended December 31, 2019, gives FY 2020 Guidance 39

6.2.2 Dec 19, 2019: REDBUD LABS STR microfluidic chip enables 1000x faster sample prep for on-cartridge magnetic bead assay 40

6.2.3 Oct 30, 2019: Merit Medical reports earnings for third quarter of 2019 41

6.2.4 Aug 14, 2019: Coloplast delivers 8% organic growth and solid performance across all business areas 44

6.2.5 Aug 14, 2019: Coloplast announcement no. 07/2019 – 9M interim financial report, 2018/19 44

6.2.6 Jul 25, 2019: Merit Medical reports earnings for second quarter of 2019 45

6.2.7 Jun 19, 2019: Japan’s MHLW approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for treatment of Relapsed/Refractory FLT3-ITD AML. Expands use to include specimens collected in EDTA 48

6.3 Government and Public Interest 49

6.3.1 Jan 27, 2020: Merit Medical issues statement regarding director nominations from starboard 49

6.4 Other Significant Developments 49

6.4.1 Jan 30, 2020: Hollister awarded National, ASCEND Agreements in Ostomy Products with Premier 49

6.5 Strategy And Business Planning 50

6.5.1 Jan 15, 2020: Merit milestones: facilities in Galway and Tijuana reach 1,000 employees 50

6.5.2 Oct 02, 2019: Hollister announces grand opening of new manufacturing facility in Kaunas, Lithuania 50

7 Appendix 52

7.1 Research Methodology 53

7.1.1 Coverage 53

7.1.2 Secondary Research 53

7.1.3 Primary Research 54

7.1.4 Market Modeling and Forecasting 55

7.1.5 Company Share Analysis 57

7.1.6 Distribution Share Analysis 57

7.1.7 Benchmarking 57

7.2 GlobalData Consulting 58

7.3 Contact Us 58

7.4 Disclaimer 59